Collaborative research studies
- Genetic variation in the NF-kappaB pathway and ovarian cancer etiology
The aim of this study is to investigate the role that genetic variation in the NF-kappaB pathway plays in ovarian cancer etiology. This study utilizes a multistage design, featuring four independent study populations.
- Follow-up of ovarian cancer genetic association and interaction studies
The goal of this research is to combine four existing GWAS for ovarian cancer to determine novel candidate genes. In addition to determining loci associated with risk, we will determine if these genetic effects are modified by environmental variables (gene-environment interaction) or other genetic loci (gene-gene interaction). The findings from these studies will be followed up with functional studies.
- Pharmacogenetics of phase II drug metabolizing enzymes — statistical pharmacogenomics
The major goals of this project are to investigate the genomic structures of phase II drug metabolizing enzymes and the pharmacogenetics of treatment for major depression and breast cancer.
- Inherited variations in drug metabolizing enzymes
The goal of this study is to explore the role of inheritance in individual variation in methyl conjugation, focusing efforts on a small number of selected MT enzymes of medical significance. Our lab is also expanding those studies to include the pathway required to generate S-adenosyl-L-methionine (AdoMet), the methyl donor for most small molecule MTs.
- Pharmacogenomics of cytosine arabinoside (ara-C) and acute myelogenous leukemia
Cytosine arabinoside (ara-C) is the single most effective drug used in the treatment of acute myelogenous leukemia (AML). However, ara-C efficacy and toxicity varies widely among patients with this disease. Therefore, we propose to study the pharmacogenomics of ara-C. The results of these studies will increase understanding of the contribution of inheritance to individual variation in ara-C efficacy and toxicity and will help move toward the goal of individualized therapy with ara-C for AML.
|
